Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
तुलना करने के लिए मीट्रिक्स | IPH | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIPHपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.2x | −2.4x | −0.4x | |
PEG अनुपात | −0.23 | −0.04 | 0.00 | |
क़ीमत/बुक | −5.1x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 12.3x | 14.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 354.9% | 182.5% | 46.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.8% | 7.6% | अनलॉक करें |